InvestorsHub Logo
Post# of 29919
Next 10
Followers 742
Posts 62036
Boards Moderated 11
Alias Born 10/05/2009

Re: Zardiw post# 29751

Tuesday, 10/24/2023 12:04:58 PM

Tuesday, October 24, 2023 12:04:58 PM

Post# of 29919
What is a global patent for a non toxic to humans, A-Z viral cure worth? One hell of lot more that the 20 Million dollar market it closed at a day ago that is for sure. $BIXT

BIXT news just came out on the global patent for the non toxic to human antiviral that had a perfect drug trial and cured Covid19 in days, putting Paxlovid to shame and the BIXT carbohydrate based drug only took 2 days not 7-10 days and the BIXT had no bounce back of the covid ( so it was1 of only 2 perfect drug trials in decade, the other was the Hep C antiviral cure that is worth billions of dollars)

https://www.otcmarkets.com/stock/BIXT/news/Bioxytran-Gets-Broad-Patent-Coverage-on-60-Viruses?id=418645

Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Press Release | 10/24/2023
Claims cover method of treating a viral infection with a lectin-binding carbohydrate

BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical-stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.

This is world wide patent people, not just the USA!!!

This could soon be the biggest thing since the invention of Penicillin, the first Antibiotic for pathogenic bacteria

This is the most undervalued Bio-Tech stock there is now!!!
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.